Dallas, TX -- (SBWIRE) -- 11/08/2011 -- ReportsnReports.com adds Datamonitor Research Report “Product Profiles: Asthma/COPD – Novel combinations edge closer to market’’ to its store.
Despite a number of well-established therapies, the asthma and COPD pipeline remains highly active. A number of products have progressed in the pipeline and significant new data have been presented at this year’s respiratory conferences. Numerous product launches are expected in the next 10 years, which will fragment the markets, although a handful of companies will maintain market dominance.
Features and benefits
Access Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for asthma and COPD.
Understand to what extent current and future therapies satisfy the main clinical unmet needs in asthma and COPD.
Assess how pipeline products compare to each other and how they will compete with established therapies.
Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
Highlights
GlaxoSmithKline dominates the asthma and COPD market with Advair. However, with a number of ICS/LABA combinations now available and generic Advair in development, the brand’s position is coming under threat. To counter this, GlaxoSmithKline is developing once-daily Relovair, which is on track to become the first once-daily ICS/LABA to reach the market.
Spiriva (Boehringer Ingelheim) is the clear gold-standard monotherapy for COPD, and remains the only LAMA available. Numerous LABA/LAMA combinations are moving through the pipeline, many of which are being directly compared to Spiriva in clinical trials. If approved, these products could offer improved efficacy with simplified treatment.
A number of companies are believed to be developing generic versions of Advair and Symbicort. Datamonitor believes that extensive clinical trial programs will be required to bring these to market, and that, if approved, they will launch as branded generics, offering a lower price discount than seen for less complex drugs.
http://www.reportsnreports.com/reports/136195-product-profiles-asthma-copd-novel-combinations-edge-closer-to-market.html
About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Blog : Market Research Reports